Interruption of perinatal transmission of hepatitis B virus(HBV) with a recombinant yeast derived hepatitis B vaccine

Objective To assess the efficacy and immunogenicity of recombinant yeast derived hepatitis B vaccine in infants born to HBsAg and HBeAg carrier mother. Methods A total of 169 neonates born to HBsAg,HBeAg both positive mothers were vaccinated with 5,5,5 μg doses of recombinant yeast derived hepatitis B vaccine by 0,1,6 months schedule.They were all followed for 3,9,12,24,36,48 months after the primary vaccination. Results 19 infants (11.24%) become HBsAg positively conversed in one year after primary vaccination, and the protective efficacy rate of interruption of perinatal transmission was 85.94%. The peak of conversion rate and titer of anti-HBs were observed in aged 9～12 months, and it decreased progressively at aged 24～36 months,the positive rates of anti_HBs were 96.43%,91.07%,85.19% and 70.0%,respectively.Conclusion The recombinant yeast derived hepatitis B vaccine has good immunogenicity and high protective efficacy in interruption of perinatal transmission, a booster dose seems necessary in aged 3-4 years after vaccination.